Please login to the form below

Not currently logged in
Email:
Password:

Teva appoints genetics specialist as its first president of global R&D

Michael Hayden will also serve as chief scientific officer at the generics company

Michael Hayden - Teva PharmaceuticalTeva Pharmaceutical has appointed genetics expert Dr Michael Hayden as its first president of global R&D and chief scientific officer.

The move shows further research ambitions for the traditionally generics-focused company, with Dr Hayden to lead the development of both branded and generic medicines.

Dr Hayden's extensive background in genetics is likely to be important for Teva too, considering the industry's increasing interest in personalised medicines.

His experience in the field includes current roles as Killam Professor of Medical Genetics at the University of British Columbia, Canada, and Canada research chair in human genetics and molecular medicine as part of a government-supported programme.

He is also the founder and director of the centre for molecular medicine and therapeutics at the University of British Columbia.

In addition, Dr Hayden has experience within the biopharma industry, having founded the biotech companies NeuroVir, Aspreva Pharmaceuticals and Xenon Genetics.

Dr Jeremy Levin, who is set to replace Shlomo Yania as Teva's president and CEO, said: “We are delighted to have Michael join us as our chief scientific officer. He brings to Teva world-renowned experience and knowledge in scientific and clinical research coupled with deep knowledge of discovery and development of medicines.”

10th May 2012

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
GK Strategy

GK is award-winning independent communications agency specialising in delivering impactful strategies for clients across the healthcare market....

Latest intelligence

ema1
The European Medicines Agency: PRIME’d for access?
Leela Barham examines the impact of the EMA's PRIME fast track system after two years...
How can pharma engage with key stakeholders on NHS service transformation?
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare consulting team, explain how pharma should make its case for change...
michael elliot
The race for an HIV ‘cure’
Supercharging therapies as pharma and patients work together...

Infographics